Precision replaces fear in new HRT guidance
On November 10, 2025, the FDA did something monumental: it began the process of removing the “black box” warnings from many systemic menopausal hormone therapy (HRT) products. For decades, these warnings signaled heightened risks for heart disease, stroke, breast cancer, and even dementia, casting a long shadow over HRT for patients and prescribers alike. But things have changed, and so must our approach.
Why did the FDA act now?
The black box warnings, applied in the early 2000s, were based on data that’s now recognized as incomplete. The pivotal Women’s Health Initiative study, for example, largely involved women well past the typical age of menopause onset and included hormone formulations that are rarely used today. Decades of follow up research have since revealed a more nuanced relationship between HRT, age at initiation, and risk.
The FDA’s decision follows expert panel reviews, comprehensive literature updates, and public comment. Simply put, evidence now shows that, for many women, the risks were overstated and the benefits underappreciated, especially when HRT is started closer to menopause.
What’s changing and what’s not?
- Risks like cardiovascular events, breast cancer, and dementia are being removed from the boxed warnings on systemic estrogen and combined estrogen-progestogen products.
- The black box for endometrial cancer remains for unopposed systemic estrogen (used in women with a uterus).
- Package inserts will still include full risk details (there’s no whitewashing of information). It’s about right sizing the message.
- FDA guidance now emphasizes HRT is ideally initiated within 10 years of menopause onset or before age 60 to optimize benefit risk.
- Manufacturers are updating product labeling in coordination with the FDA.
How does this impact pharmacy care?
For pharmacists, clinicians, and medication management leaders, this regulatory shift is a call to action, one that challenges us to move beyond a one-size-fits-all, fear driven narrative.
- Reducing barriers: The psychological and practical hurdles to HRT, often driven by the black box, may ease, allowing more women to consider treatment when appropriate.
- Tailored conversations: We must recalibrate our counseling, screening, and protocols. Age, time since menopause, symptom profile, personal/family history, and route of administration matter more than ever.
- Focus on shared decision-making: The pharmacist’s role is crucial here. We help patients weigh the timing, formulation, and unique risk factors; optimize dosing; monitor outcomes; and collaborate with their broader care team.
- Better outcomes (and potentially lower costs): Earlier, individualized use of HRT may help optimize long-term health outcomes, bone density, cardiovascular wellness, cognitive health, while reducing unnecessary fear and under treatment.
What remains critical?
Let’s be clear: removal of the black box does not mean HRT is risk-free. Personalized evaluation is non-negotiable. Key points to keep in mind:
- Not all women are good candidates. A history of breast cancer, thromboembolism, stroke, or poorly controlled hypertension still warrant caution.
- Timing matters. The benefit-risk profile is most favorable when HRT is started within about 10 years of menopause onset.
- Route matters. Systemic versus local (vaginal) estrogen have different risks and benefits. Low dose local therapies, in particular, may have been over cautioned in the past.
- Ongoing vigilance. Long term data for newer formulations and combinations are still evolving.
What should you do next?
- Update counseling scripts: Make space for nuanced discussion by emphasizing the regulatory change, but also the need for individualized decisions.
- Review your patient list: Identify peri- and early post-menopausal clients who may benefit from a fresh conversation about HRT.
- Coordinate with collaborating physicians: Ensure everyone is up to speed, aligned, and ready to re-engage in evidence-based shared decision-making.
- Educate patients: Create simple, accessible resources (FAQs, infographics, quick guides) clarifying what the FDA change means (and doesn’t mean) for them.
- Document carefully: As always, informed consent and shared decision-making should be clearly documented.
Looking ahead: Leading with knowledge, not fear
This isn’t just a regulatory update, it’s a signal that the era of blanket caution is giving way to clinical nuance. As medication experts positioned at the intersection of healthcare access and patient trust, we have an opportunity to reframe menopause care for a new generation.
Food and Drug Administration. (2025, November 10). HHS advances women’s health; removes misleading FDA warnings on hormone replacement therapy. U.S. Department of Health & Human Services. https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy
LaVito, A. (2025, November 10). U.S. FDA to drop black box warnings from menopause hormone therapies. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-chief-makary-asks-drugmakers-remove-warnings-hormone-therapy-2025-11-10/
Malhi, A. (2025, November 10). FDA to lift warnings on menopause hormone therapy, potentially boosting access. The Washington Post. https://www.washingtonpost.com/health/2025/11/10/hormone-replacement-therapy-menopause-warning-lift/
Pharmacy Times. (2025, November 10). FDA removes black boxed warning from hormone therapies for menopause. Pharmacy Times. https://www.pharmacytimes.com/view/fda-removes-black-boxed-warning-from-hormone-therapies-for-menopause
The Women’s Health Initiative Study Group. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 288(3), 321–333. https://doi.org/10.1001/jama.288.3.321
North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028
Manson, J. E., & Kaunitz, A. M. (2016). Menopause management—Getting clinical care back on track. JAMA, 315(5), 455–456. https://doi.org/10.1001/jama.2015.16939
